16.1
即放性(IR)製剤と呼ばれる従来の経口医薬品は、服用後に有効成分、略して API を速やかに放出するよう設計されており、通常は錠剤またはカプセルの形態をとります。この急速な放出は、多くの場合、薬物の迅速な吸収とそれに続く薬力学的効果をもたらしますが、その発現時期および強度は薬物の特性によって異なりま…
従来の即効性製剤は摂取直後に有効成分を放出し、素早い吸収を促進します。しかし、溶解度の低い薬剤を含む製剤は吸収が遅くなることがあります。
これらの制限を克服するために、薬物放出パターンを制御するためにモディファイドリリース用剤形態が設計されています。いくつかの種類の経口緩放性医薬品が利用可能です。
徐放性製剤は、薬物放出を維持し、治療レベルを長期間維持し、投与頻度を減らすよう設計されています。
遅延放出製剤は、腸内コーティングを多く備え、酸性の胃環境から薬物を保護し、腸内でのみ薬物放出を確実にして吸収プロファイルを最適化します。
標的放出製剤は薬剤を特定の部位に届け、治療効果を最大化し全身への曝露を最小限に抑えます。これらの製剤は即時または持続的な薬物放出を想定して設計できます。
経口分解錠剤は唾液中に素早く溶け、直接的な口腔内薬物吸収と迅速な治療効果を可能にします。従来の錠剤を飲み込むのが難しい患者に最適です。
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between immediate-release and modified-release drug formulations?
Immediate-release formulations release the active pharmaceutical ingredient promptly upon ingestion, leading to rapid absorption and quick therapeutic effects. Modified-release formulations deliberately alter drug release rate and timing to achieve specific therapeutic goals, maintain consistent drug levels, and improve patient adherence by reducing dosing frequency.
Q2: How do extended-release formulations maintain therapeutic drug levels?
Extended-release formulations utilize advanced technologies such as matrix systems and osmotic pumps to control drug release gradually over extended periods. Matrix systems embed the drug in a dissolving matrix, while osmotic pumps release drug through a semipermeable membrane opening, maintaining steady bloodstream levels and minimizing fluctuations.
Q3: Why are enteric coatings used in delayed-release formulations?
Enteric coatings protect drugs from the acidic stomach environment by resisting stomach acid and ensuring release only in the intestines. This approach optimizes absorption profiles and reduces gastric irritation, exemplified by enteric-coated aspirin, which enhances therapeutic efficacy while mitigating side effects.
Q4: What are the advantages of targeted-release drug delivery systems?
Targeted-release formulations deliver drugs directly to specific physiological sites using advanced carriers like liposomes or nanoparticles, enhancing therapeutic effects while minimizing systemic exposure. This precise delivery and localized action is particularly beneficial in treatments like cancer therapy, reducing unwanted side effects.
Q5: How do orally disintegrating tablets benefit patients with swallowing difficulties?
Orally disintegrating tablets dissolve rapidly in saliva, facilitating quick drug absorption without requiring water. This formulation enables direct buccal drug absorption and quicker therapeutic effects, making them particularly suitable for patients with swallowing difficulties or those unable to take conventional tablets.
Q6: What factors affect drug absorption in immediate-release formulations?
Drug absorption in immediate-release formulations depends on the drug's physicochemical properties. Poorly soluble drugs may exhibit slower absorption due to gradual dissolution in the gastrointestinal tract, while prodrugs require metabolic conversion to activate their effects, introducing delays in onset times.
Q7: How do modified-release formulations improve patient adherence?
Modified-release formulations reduce dosing frequency by maintaining therapeutic drug levels over extended periods, allowing patients to take medication less often. This consistent drug delivery minimizes fluctuations in blood concentration, improving treatment outcomes and making medication regimens easier for patients to follow.